Abstract: Provided is a dermo-cosmetic composition to improve rough skin that: improves chapped or dry skin, particularly roughened cuticles; improves skin texture; results in smooth skin; and has excellent safety, stability and feel. The disclosed dermo-cosmetic is characterised by having: (A) one or more of D-amino acids, their salts and derivatives; and (B) a swollen material prepared by swelling one or more of non-emulsifying cross-linked silicone with an oil which is in a liquid form at room temperature.

Abstract: The present invention provides a method for preventing or treating a disease, disorder or condition induced by retina ischemia, comprising administering to a subject in need thereof a S-allyl-L-cysteine in a therapeutically effective amount.

Abstract: The invention provides a blend of amino acid powders that have been exposed to pulsed laser radiation. The pulsed laser radiation is obtained by passing laser radiation through a device, which has a first diffraction grating, a second diffraction grating, and a refractive element positioned between the first and second diffraction gratings. Passing the laser radiation through the device cancels a portion of the laser radiation by destructive interference, and produces pulses of laser radiation by constructive interference. The blend of laser treated amino acids has been found useful in regenerating active myocardial tissue. The invention further provides a process for preparing the laser treated blend of amino acid powders and a method of regenerating active myocardial tissue with the blend.

Abstract: An object is to provide a CaSR agonist agent that has excellent CaSR agonist effects, and particularly, a pharmaceutical product that can prevent or remedy diabetes or obesity by the effect of CaSR activation. The aforementioned object is achieved by a composition that contains a compound represented by the following General Formula (I) or a salt thereof (refer to the Description for the definitions of the symbols used in the formula).

Abstract: A method for prophylactic treatment of ketosis in a calving cow, the method including orally administering to the cow within a time period of about 12 hours after calving an effective dose of from 20 to 30 g of rumen protected methionine. If the cow falls into a risk category, the cow is administered the dose of rumen protected methionine once a day on the second, third, fourth, and fifth days after calving. Also, a composition including a gelatin capsule and rumen-protected methionine contained within the gelatin capsule that may be administered to a calving cow for the prophylactic treatment of ketosis. The composition may further contain within the gelatin capsule one or more other compounds known to have efficacy on fat or glucose metabolism, such as glucose, propylene glycol, niacin, choline, chromium, calcium propionate, and glucocorticoids.

Abstract: The present invention relates generally to a method of modulating glutathione metabolism in the central nervous system of mammals and to agents for use therein. More particularly, the present invention relates to a method of up-regulating glutathione metabolism in the central nervous system by up-regulating levels of glutathione precursor molecules. The method of the present invention is particularly useful, inter alia, in the treatment and/or prophylaxis of conditions characterised by aberrant, unwanted or otherwise inappropriate central nervous system oxidation homeostasis including, but not limited to, schizophrenia.

Abstract: The invention is directed to compounds of formula I: wherein Ar, r, R3, X, and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds of formula I have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and a process and intermediates for preparing such compounds.

Abstract: The invention relates to fatty acid amides; compositions comprising an effective amount of a fatty acid amide; and methods for treating or preventing cancer, a metabolic disease or a neurodegenerative disease comprising the administration of an effective amount of a fatty acid amide.

Abstract: The present disclosure provides a method of diagnosing neurological disorders including for example, impulse control disorders, such as barbering and trichotillomania using biomarkers such as reductive capacity of urine and 8-OH-dG concentration. Still other disorders that can be diagnosed based on the measurements of makers for oxidative stress include autism and Parkinson's disease.

Abstract: A method of treating, reducing, or inhibiting biofilm formation by bacteria, the method comprising: contacting an article with a composition comprising an effective amount of a D-amino acid, said composition being essentially free of the corresponding L-amino acid, thereby treating, reducing or inhibiting formation of the biofilm, wherein the D-amino acid is selected from the group consisting of D-alanine, D-cysteine, D-aspartic acid, D-glutamic acid, D-histidine, D-isoleucine, D-lysine, D-leucine, D-asparagine, D-proline, D-glutamine, D-arginine, D-serine, D-threonine, D-valine, D-tryptophan, D-tyrosine, and a combination thereof.

Abstract: The present invention relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula (IA) or (IB): as further described herein. The invention also relates to methods for the preparation of the compounds, and to pharmaceutical compositions containing such compounds.

Abstract: Described herein is the DP2 anatgonist 2-(3-(2-((tert-butylthio)methyl)-4-(2,2-dimethyl-propionylamino)phenoxy)-4-methoxyphenyl)acetic acid, or a pharmaceutically acceptable salt thereof. Also described are methods of preparing the DP2 anatgonist, or a pharmaceutically acceptable salt thereof. Also described herein are pharmaceutical compositions suitable for administration to a mammal that include the DP2 anatgonist, or a pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating respiratory diseases or conditions, allergic diseases or conditions, inflammatory diseases or conditions, as well as other prostaglandin D2-dependent or prostaglandin D2-mediated diseases or conditions.

Abstract: The present invention relates to a novel crystal form of calcium 3-acetylaminopropane-1-sulfonate, to a process for the preparation thereof, and to the use thereof in medicaments.

Abstract: A method is provided for the prevention and treatment of patients having impaired gastro-intestinal tract function. The method comprises the steps of administering to a patient requiring same free amino acids including about 9.0% to about 17.0% glutamic acid.

Abstract: Described herein are inventions is directed to methods of treating a cardiac dysfunction and symptoms of cardiac dysfunction in a subject that includes administering an amount of probenecid effective to treat a symptom of cardiac dysfunction. The probenecid may be administered in at least one of an injection, orally, or transdermally. The amount of probenecid is sufficient to result in an improved performance on a standardized 6 minute walk test, an improved New York Heart Association (NYHA) classification, a lower diuretic dose requirement, a lower serum BNP levels, a normalization of serum sodium concentrations, and combinations thereof In an embodiment, probenecid is administered over a period of about 8 hours to about 24 hours. Probenecid may be used for short term treatments, i.e., less than a week, or it may be administered in a long term manner, i.e., over a period of weeks, months, or even years. Probenecid may be administered in an amount sufficient to treat the symptoms of cardiac dysfunction.

Abstract: The present invention relates to ABA agonist compounds which increase plant stress resistance. The invention also relates to methods of using these compounds. The invention further relates to compositions and formulations comprising the ABA agonist compounds, and uses thereof.

Abstract: Methods of treating bone cancer are disclosed. The methods comprise administering to a patient a therapeutically effective amount of a compound of formula (Ia) wherein R1, R2, R3, R4, and R5 are described herein, wherein at least two of the five R1, R2, R3, R4, and R5 substituents are always hydrogen, at least one of the five substituents is always nitro, and at least one substituent positioned adjacent to a nitro is always iodo, and pharmaceutically acceptable salts thereof.

Abstract: A method for decreasing cartilage abnormalities and preventing cartilage degradation in an animal using a combination at least one sulfur containing amino acid and manganese.

Abstract: Disclosed is a composition comprising vitamin U as an active ingredient, more precisely a composition for repairing the skin wound that contains vitamin U as an active ingredient. The composition demonstrates excellent wound healing and skin wound repairing effects.

Abstract: Among other things, the present invention provides novel isoprenyl compounds capable of effectively modulating inflammatory responses and pharmaceutical, cosmetic, cosmeceutical and topical compositions comprising these isoprenyl compounds. Anti-inflammatory compounds of the present invention are useful in treating or preventing diseases or conditions associated with inflammation. Proinflammatory compounds of the present invention are useful in treating or preventing diseases or conditions associated with suppression of inflammatory responses. Thus, the present invention also provides methods useful in the treatment or prevention of diseases or conditions associated with inflammation as well as methods useful in the treatment or prevention of diseases or conditions associated with suppression of inflammatory responses.

Abstract: The task of this invention is in use of composition containing natural metabolites—amino acids, and in method of its administration which make it possible to increase skin repigmentation through sulfurcontaining compounds rise and activation of endogenic metabolic reactions, and to get persistent normalization of melanogenesis thus improving skin integument and as a consequence patient's quality of life. Composition includes L cystine, L glutamic acid and glycine in the following quantity, mg: L cystine 85 ± 10%, L glutamic acid 85 ± 10%, Glycine 85 ± 10% The amino acid composition mentioned above must be administered 3 times a day for 5 weeks independent of meal in accordance with method of increase of skin integument repigmentation in vitiligo. The course can be repeated in 4-5 weeks.

Abstract: The invention relates to a method and composition for treatment of oxidative stress resulting from hemodialysis treatment in patients suffering from chronic kidney failure or End-Stage Renal Disease by administration of cystine, cysteine or mixtures thereof.

Abstract: The present invention concerns compositions and methods related to utilizing glycine and N-acetylcysteine for a variety of methods, including, for example, reducing deleterious effects of oxidative stress; treating and/or preventing diabetes; and/or increasing GSH levels.

Abstract: A compound which inhibits the importation of chloride into neurons and a compound which improve the outflow of chloride from neurons for the use in treatment of autism, a pharmaceutical composition for use in the treatment of autism including such compound and a pharmaceutically acceptable carrier are described.

Abstract: Methods and compositions for the treatment of iron toxicity using nitroxides, particularly 4-hydroxy-2,2,6,6-tetramethyl-1-piperidine-1-oxyl (Tempol), N-acetylcysteine (NAC), and combinations thereof.

Abstract: Embodiments of the invention include methods and compositions involving aldose reductase inhibitors for the treatment of inflammation, including uveitis and asthma.

Abstract: A composition comprising leucine, isoleucine, valine, threonine and lysine for treating chronic obstructive pulmonary disease.

Abstract: Methods and compositions comprising N-acetylcysteine amide (NAC amide) and derivatives thereof are used in treatments and therapies for human and non-human mammalian diseases, disorders, conditions and pathologies. Pharmaceutically or physiologically acceptable compositions of NAC amide or derivatives thereof are administered alone, or in combination with other suitable agents, to reduce, prevent, or counteract oxidative stress and free radical oxidant formation and overproduction in cells and tissues, as well as to provide a new source of glutathione.

Abstract: Among other things, the present invention provides novel compounds capable of effectively inhibiting inflammatory responses that are mediated by G-proteins or GPCRs in neutrophils, macrophages and platelets. In particular, the compounds of the present invention act as inhibitors of edema, inhibitors of erythema and inhibitors of MPO (myeloperoxidase), pharmaceutical compositions containing the same compounds and the use thereof for the treatment of diseases that may benefit from edema, erythema and MPO inhibition, such as inflammation (acute or chronic), asthma, autoimmune diseases, and chronic obstructive pulmonary disease (COPD) (e.g., emphysema, chronic bronchitis and small airways disease, etc.), inflammatory responses of the immune system, skin diseases (e.g., reducing acute skin irritation for patients suffering from rosacea, atopic dermatitis, seborrheic dermatitis, psoriasis), irritable bowel syndrome (e.g., Chron's disease and ulcerative colitis, etc.), and central nervous system disorders (e.g.

Abstract: Disclosed is an agent for use in the treatment or prevention of inflammatory bowel disease. Also disclosed is an agent for inhibiting the production of TNF-?. A therapeutic or prophylactic agent for inflammatory bowel disease comprising at least one amino acid selected from the group consisting of lysine, histidine, phenylalanine, methionine, tryptophan, glutamine, glycine, cysteine, cystine and threonine, the amino acid being administered at a dose of 0.1 to 4000 mg/kg per day; and a TNF-? production inhibitor comprising an amino acid selected from the group consisting of histidine, phenylalanine and tryptophan, the amino acid being administered at a dose of 0.1 to 4000 mg/kg per day.

Abstract: The present invention relates to a method of making a methionine preparation, for example for an animal feed additive. The invention also related to methods for increasing the solubility of a methionine preparation.

Abstract: The present invention relates to pharmaceutical, cosmetic and cosmeceutical topical compositions containing polyisoprenyl-protein inhibitor compounds and methods useful in the promotion of healthy epithelium and the treatment of epithelial-related conditions.

Abstract: A method is provided for the supplementation of milk, dairy products, meat products, and other food substances generally considered to be a major part of the Western diet, with substances capable of balancing the ratio of methionine and cysteine. Drug therapy with various carbamoyl thioesters or glutamate receptor antagonists can also be used, alone or in combination with dietary supplements and vitamins, to prevent or treat the pathology resulting from a Western diet.

Abstract: This invention provides methods of inhibiting replication of a poxvirus by contacting a poxvirus with a compound having formula I, formula XXI, formula XXXII, or formula XLI which in turn reduce, inhibit, or abrogate poxvirus DNA polymerase activity and/or its interaction with its processivity factor. Formula I, formula XXI, formula XXXII, or formula XLI can be utilized to treat humans and animals suffering from a poxvirus infection. Pharmaceutical compositions for treating poxvirus infected subjects are also provided.

Abstract: The present invention relates to the field of therapeutic methods to screen for compounds on the basis of their ability to influence Wnt activity. The screening process is applied to both a physical library of a series of compounds and a virtual library of compounds that affect Wnt activity. In one aspect, the virtual screening process could be carried out where a permutational library of small peptides is substituted for the small organic molecules. The inventive methods may be used to empirically test for effects on Wnt activity and may also be applied to any pair of proteins involved in protein-protein interactions.

Abstract: The present invention relates to pharmaceutical, cosmetic and cosmeceutical topical compositions containing polyisoprenyl-protein inhibitor compounds and methods useful in the promotion of healthy epithelium and the treatment of epithelial-related conditions.

Abstract: A method of preventing or inhibiting L-cystine crystallization is disclosed, using the compounds of formula I: R1a—[O]v-(-A-L-)m-A-[O]v—R1b??I wherein A, L, R1a, R1b, m, and v are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of conditions that are causally related to L-cystine crystallization, such as comprising (but not limited to) kidney stones.

Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of inflammatory diseases and disorders such as, for example, asthma and COPD.

Abstract: This invention relates to novel acetylcysteine compositions in solution, comprising acetylcysteine and which are substantially free of metal chelating agents, such as EDTA. Further, this invention relates to methods of making and using the acetylcysteine compositions. The present compositions and methods are designed to improve patient tolerance and compliance, while at the same time maintaining the stability of the pharmaceutical formulation. The compositions and methods of this invention are useful in the treatment of acetaminophen overdose, acute liver failure, various cancers, methacrylonitrile poisoning, reperfusion injury during cardio bypass surgery, and radiocontrast-induced nephropathy, and can also be used as a mucolytic agent.

Abstract: Disclosed herein are substituted fluoromethanes; pharmaceutical compositions comprising a therapeutically effective amount of the same; processes for preparing these fluoromethanes; and methods of using the same in alleviating infection and parasitism. Also disclosed are methods for identifying substituted fluoromethanes for modulating the activity of receptors and enzymes that bind and/or modify phosphate containing ligands and substrates.

Abstract: Compositions for treating hair are disclosed. Methods of making and using compositions for treating hair are also disclosed.

Abstract: A method for enhancing the overall beneficial immune system response in a host that works in conjunction with the host's natural immune system response to enhance the host's ability to eliminate infectious microbes while simultaneously suppressing the toxicity of the immune system response to the host. Allium related organosulfur compounds are disclosed which have a various antimicrobial immunomodulatory properties that work together with the host's immune system in the prevention and treatment of disease. Prophylactic and therapeutic treatment is provided by administering an allium related organosulfur compound such that a localized thiosulfinate is caused to be non-enzymatically formed in response to localized generation by activated immune system cells of reactive oxygen species such as hydrogen peroxide. Suitable allium related organosulfur compounds may be administered to the host in an efficient manner through the use of S-AllylMercapto-N-AcetylCysteine (SAMNAC) or similar prodrugs.

Abstract: This invention relates to novel 4-dimethylaminobutyric acid derivatives of the formula wherein A1, A2, R1, m and n are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds inhibit carnitine palmitoyl transferase (CPT) activity, in particular CPT2 activity, and can be used as medicaments in methods for the treatment of diseases modulated by CPT2 inhibitors.

Abstract: In one aspect, the present invention provides chemoprotectant compositions that each comprise at least two of the chemoprotectants disclosed herein. The chemoprotectant compositions of the invention are useful, for example, for ameliorating at least one adverse effect of chemotherapy. In another aspect, the present invention provides methods of ameliorating at least one adverse effect of chemotherapy, the methods each comprising the step of administering to a subject undergoing chemotherapy an amount of a chemoprotectant composition that is effective to ameliorate at least one adverse effect of the chemotherapy.

Abstract: The present invention relates to the field of therapeutic and diagnostic agents and more specifically to compounds of formula (I) that are inhibitors of matrix-metalloproteinases (MMPs) and are useful in the treatment of diseases related thereto such as cardiovascular diseases, inflammatory diseases and malignant diseases. One embodiment of the invention is a compound of formula (I) labeled with a 18-fluorine atom having matrix metalloproteinase inhibitory activity suitable for diagnostic imaging. Also disclosed in the present invention is a pharmaceutical composition comprising the inhibitors of matrix-metalloproteinases (MMPs) of the invention or the corresponding labeled compounds useful as diagnostic imaging agents of the invention in a form suitable for mammalian administration.

Abstract: The invention relates to products and methods for increasing the productivity in farming by improving the fertility of healthy farming mammals. More in particular, the invention relates to products and methods for improving the fertility of animals by reducing placental insufficiency. According to the invention, this is obtained by providing a product which is enriched in L-arginine. The arginine products of the invention may be applied to improve fertility, which may be used in improving the yield in viable offspring of an animal livestock.

Abstract: It is an object to provide a radical scavenger, an active oxygen-scavenging agent and the like, which are highly efficacious clinically and novel, and so as to attain the object, 3,4-dihydroxyphenylalanine derivatives such as N-?-alanyl-5-S-glutathionyl-3,4-dihydroxyphenylalanine (5-S-GAD) or pharmaceutically acceptable salts thereof are contained as an active ingredient.

Abstract: According to an aspect of the present invention, the present invention provides medical devices which contain one or more polymeric regions that are at least partially biodisintegrable in bodily fluid. These devices may be implanted or inserted into a subject for treatment of various diseases, disorders and conditions.

Abstract: The invention provides methods for treating or preventing alcohol-related disorders or craving-related disorders comprising administering an effective amount of N-acetylcysteine or a pharmaceutically acceptable salt thereof to a patient to treat or prevent the alcohol or craving disorders. Methods for enhancing drug delivery and improving treatment outcomes are also described.

Abstract: This invention relates to the field of biologically active compounds and specifically to closthioamides, pharmaceutical compositions comprising these compounds, and their use as antibiotic, antifungal, and/or cytotoxic agent.